Neurocrine Biosciences (NBIX) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Neurocrine Bio. (NBIX) PT Raised to $138 at Stifel; Nice Ingrezza Beat and Better TRx Commentary
August 3, 2021 5:54 PM EDTStifel analyst Paul Matteis raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $138.00 (from $136.00) while maintaining a Buy rating following results.
The analyst commented, "We are reiterating our Buy rating on NBIX on the back of a solid 2Q for... More
